Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.

作者信息

Redlich Kurt, Schett Georg, Steiner Günter, Hayer Silvia, Wagner Erwin F, Smolen Josef S

机构信息

University of Vienna, Vienna, Austria.

出版信息

Arthritis Rheum. 2003 Dec;48(12):3308-19. doi: 10.1002/art.11358.

DOI:10.1002/art.11358

PMID:14673982

Abstract

摘要

相似文献

Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.

Arthritis Rheum. 2003 Dec;48(12):3308-19. doi: 10.1002/art.11358.

[Redefining treatment of rheumatic arthritis with anti-cytokines].

Rev Med Suisse. 2007 Mar 21;3(103):715-7.

The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.

Rheum Dis Clin North Am. 2004 May;30(2):365-80, vii. doi: 10.1016/j.rdc.2004.01.005.

Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.

Arthritis Rheum. 2004 Sep;50(9):3049-50; author reply 3050-1. doi: 10.1002/art.20640.

Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade: comment on the article by Buch et al.

Arthritis Rheum. 2005 Jan;52(1):364-5; author reply 365. doi: 10.1002/art.20769.

The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.

J Rheumatol. 2004 Oct;31(10):1881-4.

How antirheumatic drugs protect joints from damage in rheumatoid arthritis.

Arthritis Rheum. 2008 Oct;58(10):2936-48. doi: 10.1002/art.23951.

[Treatment of rheumatoid arthritis with cytokine antagonists].

Z Arztl Fortbild Qualitatssich. 1999 Mar;93(2):101-4.

Anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor agents.

Ann Rheum Dis. 2005 Dec;64(12):1807. doi: 10.1136/ard.2005.040436.

Emerging biologic drugs for the treatment of rheumatoid arthritis.

Autoimmun Rev. 2005 Nov;4(8):537-41. doi: 10.1016/j.autrev.2005.04.016.

引用本文的文献

MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases.

Adv Ther. 2022 Jul;39(7):3403-3422. doi: 10.1007/s12325-022-02168-4. Epub 2022 May 25.

Comparison of long-term efficacy between biological agents following tumor necrosis factor inhibitor failure in patients with rheumatoid arthritis: a prospective cohort study.

Ther Adv Musculoskelet Dis. 2021 Nov 24;13:1759720X211060910. doi: 10.1177/1759720X211060910. eCollection 2021.

MicroRNA-146a governs fibroblast activation and joint pathology in arthritis.

J Autoimmun. 2017 Aug;82:74-84. doi: 10.1016/j.jaut.2017.05.006. Epub 2017 May 22.

Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.

Drug Saf. 2015 Oct;38(10):869-88. doi: 10.1007/s40264-015-0336-2.

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure.

Biologics. 2012;6:191-9. doi: 10.2147/BTT.S32244. Epub 2012 Jul 2.

Effects of 18β-Glycyrrhetinic acid in hTNFtg mice - a model of rheumatoid arthritis.

Wien Klin Wochenschr. 2012 Mar;124(5-6):170-6. doi: 10.1007/s00508-011-0103-z. Epub 2012 Jan 3.

Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain.

Int J Inflam. 2011;2011:727634. doi: 10.4061/2011/727634. Epub 2011 Jun 28.

A proposal of simple calculation (ERI calculator) to predict the early response to TNF-α blockers therapy in rheumatoid arthritis.

Rheumatol Int. 2012 Feb;32(2):349-56. doi: 10.1007/s00296-010-1619-7. Epub 2010 Nov 26.

Osteoclastogenesis and arthritis.

Clin Exp Med. 2011 Sep;11(3):137-45. doi: 10.1007/s10238-010-0117-2. Epub 2010 Nov 11.

To switch or to change class-the biologic dilemma in rheumatoid arthritis.

Nat Rev Rheumatol. 2010 May;6(5):301-5. doi: 10.1038/nrrheum.2010.45. Epub 2010 Apr 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验